GCM
AMAG

Greywolf Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Greywolf Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-662,330
Closed -$15.8M – 8
2016
Q2 		$15.8M Buy
+662,330
New +$15.2M 3.44% 5
2015
Q2 		– Sell
-431,552
Closed -$23.3M – 12
2015
Q1 		$23.3M Sell
431,552
-431,553
-50% -$20.6M 6.26% 7
2014
Q4 		$35.9M Buy
+863,105
New +$31.2M 6.36% 6

Other funds holding AMAG

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SIM
Stelliam Investment Management New York $404M AUM 5.1% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Greywolf Capital Management's AMAG Position: Q3 2016 in Review

Greywolf Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q3 2016, closing a stake of 662,330 shares — an estimated $15.8M sold.

Greywolf Capital Management first reported a position in AMAG in Q4 2014 and held it in 3 quarters. The position peaked at $35.9M in Q4 2014. 178 funds tracked by Wall St. Rank hold AMAG as of Q3 2016.

  • Greywolf Capital Management reported no remaining AMAG Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Greywolf Capital Management sold 662,330 AMAG Pharmaceuticals shares in Q3 2016, an estimated $15.8M.
  • Greywolf Capital Management first reported a position in AMAG Pharmaceuticals in Q4 2014 and held it in 3 quarters.
  • Greywolf Capital Management's AMAG Pharmaceuticals position peaked at $35.9M in Q4 2014.
  • 178 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2016.

Based on Greywolf Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.